HIV NC 2019

• (O1) Antiretroviral treatment initiated at high CD4 cell counts does not normalize cerebrospinal fluid markers of immune activation
• (O2) Employment of people living with HIV approaching that of the HIV-negative population irrespective of migrant status and sexual orientation
• (O3) The burden of comorbidities in people living with HIV (PLHIV) in Central Denmark Region
• (O4) Activated and exhausted CD8 T-cells differentiate aviremic HIV-2 infected from seronegative individuals
• (O5) A long-term study of 337 hepatitis D virus (HDV) and hepatitis B virus co-infected patients: the impact of HDV viremia on liver-related outcomes
• (O6) 4 week treatment for hepatitis C – a randomized controlled trial (4RIBC)
• (P1) Features of early HIV-specific CD8 T cell responses in association with protective HLA-alleles
• (P2) Cytotoxic lymphocyte protease granzyme M is differentially expressed in PBMCs of Elite Controllers and targets HIV-1 Gag
• (P3) Increased exhaustion of gut and blood CD4+ T cells in people living with HIV with insufficient immunologic response to antiretroviral therapy
• (P4) Impaired homing properties of CD8+ T cells in HIV-1 infected patients receiving early anti-retroviral therapy
• (P5) The inhibitory effect of HIV-1 specific CD8+ T cells on the establishment and maintenance of HIV-1 latent reservoir
• (P6) Survival of people living with HIV in Central Denmark Region during the pre-, early- and late HAART era
• (P7) Use of integrase inhibitors during pregnancy in Women Living With HIV in Denmark
• (P8) Half of patients with baseline HIV-RNA >500,000 copies/mL do not reach the treatment goal of <50 within 6 months
• (P9) Clinical presentation, treatment, and outcome of HIV-associated hematologic malignancies in people living with HIV
• (P10) Preliminary observations and results of pre-exposure prophylaxis of HIV after 10 months of inclusion in a Swedish MSM cohort at Venhälsan, Stockholm
• (P11) Longitudinal trends in self-reported side effects and prescribed 3rd agent in ART
• (P12) Causes of Death in People Living with HIV (PLHIV) at Venhälsan, Södersjukhuset, Stockholm, 1996-2019
• (P13) Incidence of tuberculosis and the need of prophylactic treatment in people living with HIV on anti-retroviral therapy, trends in Stockholm 1996-2013
• (P14) Prevalence and risk factors for depression in persons living with HIV in Norway
• (P15) Comparing The Euroqol 5 Dimension And Patient Generated Index In Assessing Health Related Quality Of Life Among Pregnant Women Living With HIV In Kenya.
• (P16) HIV status disclosure and fears of negative social consequences among pregnant women in antenatal care: Multi-centre survey in western Kenya
• (P17) Food security, viral suppression and depression in migrant workers living with HIV in Chiang Mai, Thailand
• (P18) Towards HIV diagnostics at the point-of-care using rolling circle amplification and microfluidic signal enhancement
• (P19) Biological characteristics of Transmitted founder HIV-1 viruses: sensitivity to Interferon alpha, replication kinetics and virus production
• (P20) Selection of non-synonymous amino acid substitution by HIV during early infection: Variants identified by high-throughput sequencing
• (P21) Alterations in the Gut Microbiome of HIV infected patients under Antiretroviral Therapy
• (P22) Correlation of inflammatory biomarkers with the HIV reservoir under long-term suppressive ART in India
• (P23) Systemic inflammation in people living with HIV on successful therapy: higher risk of neurological diseases and inflamm-aging
• (P24) Role of cervicovaginal microbiome in HIV-1 transmission in HIV-exposed seronegative (ESN) women
• (P25) Proteo-transcriptomics analysis of blood-cell populations with specific to HIV-infection
• (P26) Optimization of transcriptomics data analysis to accurate identification of immune signatures, clinical relevance and biomarkers discovery in infectious diseases
• (P27) Molecular Mechanism of N155H/E92Q Resistance to HIV-1 Integrase Inhibitors
• (P28) Investigating HIV-1 resistance patterns to protease inhibitors in HIV-1 infected patients failing second-line therapy in South Africa
• (P29) Protease inhibitor drug resistance mutations in minor viral quasispecies of HIV-1 infected patients failing second line therapy in South Africa
• (P30) HIV-1 drug resistance genotyping from dried blood spots using the Free Virus Elution (FVE) Technique, in Zimbabwe
• (P31) High throughput sequencing for in depth analysis of pre-treatment HIV-1 drug resistance in Sweden
• (P32) Rational design and characterization of novel HIV-1 capsid inhibitors
• (P33) Design and Characterization of Fluorogenic Inhibitors to detect Active HIV-1 Protease during the Viral Assembly Process
• (P34) Antibody responses to PCV-10 and Streptococcus pneumoniae nasal carriage in HIV infected children in Ethiopia
• (P35) Barriers and facilitators to participate in a needle exchange program for women who inject drugs
• (P36) Risk behaviours and prevalence of blood borne infections in young people seeking treatment or advice for drug use – the potential of dried blood spots.
• (P37) Viral Hepatitis Prevalence and Crises-Driven Migration: Shifting Disease Landscapes in Northern Europe
• (P38) The Prevalence of Hepatitis C virus, Hepatitis B virus, and HIV Infection among Prisoners in Stockholm County
• (P39) Retrospective analysis of co-medication patterns in patients treated for HCV, and potential DDIs with DAAs, in Norway during 2014-2018 using the NorPD.
• (P40) Real-world effectiveness of elbasvir/grazoprevir in the treatment of patients with hepatitis C virus genotype 1a infection in Norway
• (P41) A MODEL OF CARE FOR PEOPLE ATTENDING DRUG TREATMENT CENTERS AIMING AT HEPATITIS C ELIMINATION BY 2022. A PART OF THE C- FREE SOUTH STRATEGY
• (P42) Oral Health inPatients with Chronic Hepatitis B Infection vs Chronic Hepatitis B